The Importance of Managing Fatigue in Multiple Sclerosis
  • CME
  • CE

Fatigue is a critically important symptom to recognize in persons with multiple sclerosis. Here’s my approach to understanding and treating this “invisible” symptom.
Patricia K. Coyle, MD, FAAN, FANA
Physicians: maximum of 0.25 AMA PRA Category 1 Credits
Registered Nurses: 0.25 Nursing contact hours
Released: August 26, 2021 Expiration: August 25, 2022

Learning Objectives

Upon completion of this activity, participants should be able to:
  • Adopt best practices in recognizing and managing comorbidities in patients with MS

Acknowledgements

Supported by educational grants from
Biogen
Bristol-Myers Squibb

Information on this Educational Activity

In accordance with the Accreditation Council for Continuing Medical Education’s (ACCME) Standards for Integrity and Independence in Continuing Education, CMSC require that individuals in a position to control the content of an educational activity disclose all financial relationships with ineligible companies. CMSC mitigate all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all their educational programs. Furthermore, CMSC seek to verify that all scientific research referred to, reported, or used in a CE activity conforms to the generally accepted standards of experimental design, data collection, and analysis. CMSC is committed to providing learners with high-quality CE activities that promote improvements in health care and not those of a commercial interest.

The program faculty reported the following relevant financial relationships that they have with ineligible companies:

Faculty

Patricia K. Coyle, MD, FAAN, FANA

Professor and Vice Chair (Clinical Affairs)
Director, MS Comprehensive Care Center
Department of Neurology
Stony Brook University Hospital
Stony Brook, New York

Patricia K. Coyle, MD, FAAN, FANA, has disclosed that she has received consulting fees from Accordant, Alexion, Bayer, Biogen, Bristol-Myers Squibb, Celgene, EMD Serono, Genentech/Roche, GlaxoSmithKline, Janssen, Mylan, Novartis, Sanofi Genzyme, TG Therapeutics, and Viela Bio; funds for research support from Alkermes, Corrona, Genentech/Roche, MedDay, and NINDS; and fees for non-CME/CE services from Biogen and Janssen.

The planners, content developers, reviewers, and other staff at Clinical Care Options, LLC have disclosed no relevant financial relationships.

All of the relevant financial relationships listed for these individuals have been mitigated.

The planners, reviewers, editors, staff, or other members at CMSC who are in a position to control content have no relevant financial relationships with ineligible companies.

Disclosure of Unlabeled Use

CMSC require faculty to disclose to the attendees when products or procedures being discussed are off-label, unlabeled, experimental, and/or investigational (not FDA approved); and any limitations on the information that is presented, such as data that are preliminary or that represent ongoing research, interim analyses, and/or unsupported opinion. Faculty in this activity may discuss information about pharmaceutical agents that is outside of US Food and Drug Administration approved labeling. This information is intended solely for continuing education and is not intended to promote off-label use of these medications. If you have questions, contact the medical affairs department of the manufacturer for the most recent prescribing information.

Disclaimer

CMSC present this information for educational purposes only. The content is provided solely by faculty who have been selected because of recognized expertise in their field. Participants have the professional responsibility to ensure that products are prescribed and used appropriately on the basis of their own clinical judgment and accepted standards of care. CMSC and the commercial supporter(s) assume no liability for the information herein.

Target Audience

This program is intended for neurologists, primary care physicians, nurse practitioners, nurses, and other healthcare providers who care for patients with MS.

Goal

The goal of this activity is to improve the knowledge and competence of learners to recognize and manage comorbidities and MS symptoms in patients with MS.

Accreditation

Joint Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by the Consortium of Multiple Sclerosis Centers (CMSC) and Clinical Care Options, LLC (CCO). CMSC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Credit Designation

The Consortium of Multiple Sclerosis Centers designates this enduring material for a maximum of 0.25 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nursing Continuing Education

Credit Designation

The Consortium of Multiple Sclerosis Centers designates this enduring material for 0.25 contact hours of nursing continuing professional development.

Program Medium

This program has been made available online.

Instructions for Credit

Participation in this self-study activity should be completed in approximately 0.25 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from August 26, 2021, through August 25, 2022:

1. Register online at http://www.clinicaloptions.com.
2. Read the target audience, learning objectives, and faculty disclosures.
3. Study the educational activity online or printed out.
4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 100% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME/CE activities completed can be found on the "CME/CE Manager" page. There are no costs/fees for this activity.

Related Content

Slides from a presentation that educates clinicians on Huntington disease and the management of chorea

Victor W. Sung, MD Released: September 17, 2021

In Neuroscience Research Review (GME Research Review), Drs Gupta and McEvoy respond to current articles on tardive dyskinesia (TD) including pharmacologic treatments and identification via the AIMS exam

Sanjay Gupta, MD Joseph P. McEvoy, MD Physicians: maximum of 0.75 AMA PRA Category 1 Credits Registered Nurses: 0.75 Nursing contact hours Pharmacists: 0.75 contact hours (0.075 CEUs) Physician Assistants: maximum of 0.75 hours of AAPA Category I CME credits Released: August 31, 2021 Expired: August 30, 2022

In Neuroscience Research Review (GME Research Review), Drs Gupta and McEvoy respond to current articles on tardive dyskinesia (TD) including pharmacologic treatments and identification via the AIMS exam

Sanjay Gupta, MD Joseph P. McEvoy, MD Physicians: maximum of 0.75 AMA PRA Category 1 Credits Registered Nurses: 0.75 Nursing contact hours Pharmacists: 0.75 contact hours (0.075 CEUs) Physician Assistants: maximum of 0.75 hours of AAPA Category I CME credits Released: August 31, 2021 Expired: August 30, 2022

Expert insights on clinical implications and treatment of sleep disorders and obesity in patients with MS

Patricia K. Coyle, MD, FAAN, FANA Patricia Melville, ANP-BC, MSCN Physicians: maximum of 0.5 AMA PRA Category 1 Credits Registered Nurses: 0.5 Nursing contact hours Released: August 27, 2021 Expired: August 26, 2022

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue